AstraZeneca announces three-year cost-cutting programme
Business · First reported 30 Oct, 11:36 · Updated 11:51
AstraZeneca plans to cut costs by $1.5 billion (£1.1 billion) annually through a three-year overhaul, with savings intended to support investment in its drug pipeline. The available reports provide different levels of detail: one outlines the programme and financial results, while the other focuses on the company’s workforce.
- AstraZeneca announced a three-year restructuring programme intended to save $1.5 billion (£1.1 billion) per year; it said the savings would be reinvested, principally in its drug pipeline.
- The company said the programme could cost up to $2 billion (£1.5 billion) in restructuring charges, but did not specify where savings would come from or whether jobs would be affected.
- AstraZeneca employs 100,000 people worldwide, including around 10,000 in the UK; its third-quarter pre-tax profits rose 22% to $3.96 billion, according to the fuller report.
Summary written by Lux AI from 2 articles
Key facts
- Annual savings target
- $1.5 billion (£1.1 billion)
- Programme duration
- Three years
- Potential restructuring charges
- Up to $2 billion (£1.5 billion)
- Global workforce
- 100,000 employees, including around 10,000 in the UK
- Third-quarter pre-tax profits
- $3.96 billion, up 22%
Source spectrum
Far left
Left
Lean left
Centre
Lean right
Right
Far right
Unrated
Left 0 · Centre 1 · Right 0 of 1 rated sources · +1 unrated
All coverage
Coverage over time
LeftCentreRight
Articles per hour since first reported, by side.
Ownership
- Unknown 100% (2)
Share of the 2 sources by owner type.